English

Neurogene Inc.

EDGAR

AQXP Quarterly report (10-Q) · filed 2026-08-11

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 925K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2025 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-17.5 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -77200000 USD Source
Operating Cash Flow: -59700000 USD Source

Free cash flow

-17.6 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -77200000 USD Source
Operating Cash Flow: -59700000 USD Source
Capital Expenditure: 1183000 USD Source
Capital Expenditure: 1055000 USD Source

Cash and cash equivalents: 112 million USD 2026-06-30 Source
Exact value

112485000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 15.8 million shares 2026-06-30 Source
Exact value

15830504 shares

Reported share-count change

10.94% · 1.56 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

14269264 shares · 2025-06-30· Source
15830504 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-111 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -20953000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -90400000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -65600000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -30934000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -34488000 USD · 2026-04-01 – 2026-06-30 Source

Capital expenditure

890 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 1055000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 928000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 1183000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 1055000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 281000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 635000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 281000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-11.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2025-12-31
Operating income: 10 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 4 of 11 periods available· newest 2025-12-31
Total liabilities: 4 of 11 periods available· newest 2025-12-31
Current assets: 4 of 11 periods available· newest 2025-12-31
Current liabilities: 4 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 4 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

USD 925,000

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 925000 = -925000 USD

925000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Neurogene Inc. · 2025-12-31 Neurogene Inc. (edgar:1404644) Year-over-year change in Revenue: -925000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1914007 Filing: 000140464426000019 Input fundies:Revenue: 925000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1914887 Filing: 000140464426000019
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 15.3 million

Prior period

−USD 75.1 million

2024-01-01 – 2024-12-31
Current period

−USD 90.4 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-90400000 − -75100000 = -15300000 USD

-75100000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-90400000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Neurogene Inc. · 2025-12-31 Neurogene Inc. (edgar:1404644) Year-over-year change in Net income: -15300000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -90400000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1374523 Filing: 000140464426000019 Input fundies:NetIncome: -75100000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1374678 Filing: 000140464426000019
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 6.6 million

Prior period

−USD 70.6 million

2024-01-01 – 2024-12-31
Current period

−USD 77.2 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-77200000 − -70600000 = -6600000 USD

-70600000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-77200000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Neurogene Inc. · 2025-12-31 Neurogene Inc. (edgar:1404644) Year-over-year change in Operating cash flow: -6600000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -77200000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1374948 Filing: 000140464426000019 Input fundies:OperatingCashFlow: -70600000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1375132 Filing: 000140464426000019
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+46.4%

Prior period

USD 808,000

2024-01-01 – 2024-12-31
Current period

USD 1.18 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1183000 − 808000 = 375000 USD

808000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1183000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Neurogene Inc. · 2025-12-31 Neurogene Inc. (edgar:1404644) Year-over-year change in Capital expenditure: 375000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1183000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1331525 Filing: 000140464426000019 Input fundies:CapitalExpenditure: 808000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1332114 Filing: 000140464426000019
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 103.33 million
Operating income −USD 103.33 million
Tax, interest and other Derived −USD 12.93 million
Net income −USD 90.4 million

Cash

Operating cash flow −USD 77.2 million
Capital expenditure USD 1.18 million
Free cash flow Derived −USD 78.38 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Operating loss: operating costs were 230% of revenue.
2023 Not shown: operating income or net income is not reported.
2024 Operating loss: operating costs were 9,030% of revenue.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	25000000	57624000 Derived	-32624000	-1039000 Derived	-31585000	-31626000 Derived	Source 2018-01-01 – 2018-12-31: 25000000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -32624000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -31585000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -31577000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 49000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	0	55583000 Derived	-55583000	-19283000 Derived	-36300000	-51721000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -55583000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -36300000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -51400000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 321000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	925000	83530000 Derived	-82605000	-7505000 Derived	-75100000	-71408000 Derived	Source 2024-01-01 – 2024-12-31: 925000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -82605000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -75100000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -70600000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 808000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	0	103328000 Derived	-103328000	-12928000 Derived	-90400000	-78383000 Derived	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -103328000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -90400000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -77200000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 1183000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Revenue	25000000	Revenue: 25000000 Open source
20232023-12-31	Revenue	0	Revenue: 0 Open source
20242024-12-31	Revenue	925000	Revenue: 925000 Open source
20252025-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 25000000 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 925000 Open source Revenue: 0 Open source
20252025-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 925000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -8,930.3% 2024

Net margin -8,118.9% 2024

Free cash flow margin -7,719.8% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	-130.5%	Operating Income: -32624000 Open source Revenue: 25000000 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -55583000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	-8,930.3%	Operating Income: -82605000 Open source Revenue: 925000 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -103328000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	-126.3%	Net Income: -31585000 Open source Revenue: 25000000 Open source
20232023-12-31	Net margin	Not reported	Net Income: -36300000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	-8,118.9%	Net Income: -75100000 Open source Revenue: 925000 Open source
20252025-12-31	Net margin	Not reported	Net Income: -90400000 Open source Revenue: 0 Open source
20182018-12-31	Free cash flow margin	-126.5%	Revenue: 25000000 Open source Operating Cash Flow: -31577000 Open source Capital Expenditure: 49000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -51400000 Open source Capital Expenditure: 321000 Open source
20242024-12-31	Free cash flow margin	-7,719.8%	Revenue: 925000 Open source Operating Cash Flow: -70600000 Open source Capital Expenditure: 808000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -77200000 Open source Capital Expenditure: 1183000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -77.2M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	-31577000	Operating Cash Flow: -31577000 Open source
20232023-12-31	Operating cash flow	-51400000	Operating Cash Flow: -51400000 Open source
20242024-12-31	Operating cash flow	-70600000	Operating Cash Flow: -70600000 Open source
20252025-12-31	Operating cash flow	-77200000	Operating Cash Flow: -77200000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -78.4M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	-31626000	Operating Cash Flow: -31577000 Open source Capital Expenditure: 49000 Open source
20232023-12-31	Free cash flow	-51721000	Operating Cash Flow: -51400000 Open source Capital Expenditure: 321000 Open source
20242024-12-31	Free cash flow	-71408000	Operating Cash Flow: -70600000 Open source Capital Expenditure: 808000 Open source
20252025-12-31	Free cash flow	-78383000	Operating Cash Flow: -77200000 Open source Capital Expenditure: 1183000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

8.2% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Liabilities / assets	6.4%	Total Liabilities: 4946000 Open source Total Assets: 77618000 Open source
20232023-12-31	Liabilities / assets	16.4%	Total Liabilities: 36549000 Open source Total Assets: 222573000 Open source
20242024-12-31	Liabilities / assets	7.6%	Total Liabilities: 25355000 Open source Total Assets: 335730000 Open source
20252025-12-31	Liabilities / assets	8.2%	Total Liabilities: 23717000 Open source Total Assets: 288604000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

16.56× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Current assets / current liabilities	16.68×	Current Assets: 77165000 Open source Current Liabilities: 4627000 Open source
20232023-12-31	Current assets / current liabilities	8.72×	Current Assets: 200348000 Open source Current Liabilities: 22973000 Open source
20242024-12-31	Current assets / current liabilities	20.84×	Current Assets: 315923000 Open source Current Liabilities: 15157000 Open source
20252025-12-31	Current assets / current liabilities	16.56×	Current Assets: 271770000 Open source Current Liabilities: 16411000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 37 million Exact value Exact value: -37002000 USD 2016-01-01 – 2016-12-31: -37002000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Neurogene Inc. · 2016-12-31 Neurogene Inc. (edgar:1404644) Net Income: -37002000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -37002000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312519066506/aqxp-20181231.xml#639059 Filing: 000119312519066506 The citation records this snapshot. The page link may show a newer release later.	−USD 30.23 million Exact value Exact value: -30226000 USD 2016-01-01 – 2016-12-31: -30226000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neurogene Inc. · 2016-12-31 Neurogene Inc. (edgar:1404644) Operating Cash Flow: -30226000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -30226000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312519066506/aqxp-20181231.xml#638791 Filing: 000119312519066506 The citation records this snapshot. The page link may show a newer release later.	USD 713,000 Exact value Exact value: 713000 USD 2016-01-01 – 2016-12-31: 713000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neurogene Inc. · 2016-12-31 Neurogene Inc. (edgar:1404644) Capital Expenditure: 713000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 713000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312519066506/aqxp-20181231.xml#641093 Filing: 000119312519066506 The citation records this snapshot. The page link may show a newer release later.	−USD 30.94 million Calculation and evidence -30226000 − 713000 USD Exact free cash flow: -30939000 USD 2016-01-01 – 2016-12-31: -30226000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 713000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neurogene Inc. · 2016-12-31 Neurogene Inc. (edgar:1404644) Free cash flow: -30939000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -30226000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312519066506/aqxp-20181231.xml#638791 Filing: 000119312519066506 Input fundies:CapitalExpenditure: 713000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312519066506/aqxp-20181231.xml#641093 Filing: 000119312519066506 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 50.18 million Exact value Exact value: -50183000 USD 2017-01-01 – 2017-12-31: -50183000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Neurogene Inc. · 2017-12-31 Neurogene Inc. (edgar:1404644) Net Income: -50183000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -50183000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/nltx-20191231.xml#91498 Filing: 000119312520071545 The citation records this snapshot. The page link may show a newer release later.	−USD 44.72 million Exact value Exact value: -44718000 USD 2017-01-01 – 2017-12-31: -44718000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neurogene Inc. · 2017-12-31 Neurogene Inc. (edgar:1404644) Operating Cash Flow: -44718000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44718000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/nltx-20191231.xml#101630 Filing: 000119312520071545 The citation records this snapshot. The page link may show a newer release later.	USD 494,000 Exact value Exact value: 494000 USD 2017-01-01 – 2017-12-31: 494000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neurogene Inc. · 2017-12-31 Neurogene Inc. (edgar:1404644) Capital Expenditure: 494000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 494000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/nltx-20191231.xml#102012 Filing: 000119312520071545 The citation records this snapshot. The page link may show a newer release later.	−USD 45.21 million Calculation and evidence -44718000 − 494000 USD Exact free cash flow: -45212000 USD 2017-01-01 – 2017-12-31: -44718000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 494000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neurogene Inc. · 2017-12-31 Neurogene Inc. (edgar:1404644) Free cash flow: -45212000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44718000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/nltx-20191231.xml#101630 Filing: 000119312520071545 Input fundies:CapitalExpenditure: 494000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/nltx-20191231.xml#102012 Filing: 000119312520071545 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 31.59 million Exact value Exact value: -31585000 USD 2018-01-01 – 2018-12-31: -31585000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Neurogene Inc. · 2018-12-31 Neurogene Inc. (edgar:1404644) Net Income: -31585000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31585000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/nltx-20191231.xml#91350 Filing: 000119312520071545 The citation records this snapshot. The page link may show a newer release later.	−USD 31.58 million Exact value Exact value: -31577000 USD 2018-01-01 – 2018-12-31: -31577000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neurogene Inc. · 2018-12-31 Neurogene Inc. (edgar:1404644) Operating Cash Flow: -31577000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31577000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/nltx-20191231.xml#97524 Filing: 000119312520071545 The citation records this snapshot. The page link may show a newer release later.	USD 49,000 Exact value Exact value: 49000 USD 2018-01-01 – 2018-12-31: 49000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neurogene Inc. · 2018-12-31 Neurogene Inc. (edgar:1404644) Capital Expenditure: 49000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 49000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/nltx-20191231.xml#98720 Filing: 000119312520071545 The citation records this snapshot. The page link may show a newer release later.	−USD 31.63 million Calculation and evidence -31577000 − 49000 USD Exact free cash flow: -31626000 USD 2018-01-01 – 2018-12-31: -31577000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 49000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neurogene Inc. · 2018-12-31 Neurogene Inc. (edgar:1404644) Free cash flow: -31626000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -31577000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/nltx-20191231.xml#97524 Filing: 000119312520071545 Input fundies:CapitalExpenditure: 49000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/nltx-20191231.xml#98720 Filing: 000119312520071545 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 69.44 million Exact value Exact value: -69442000 USD 2019-01-01 – 2019-12-31: -69442000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Neurogene Inc. · 2019-12-31 Neurogene Inc. (edgar:1404644) Net Income: -69442000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -69442000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828021005630/nltx-20201231.htm#945636 Filing: 000162828021005630 The citation records this snapshot. The page link may show a newer release later.	−USD 15.39 million Exact value Exact value: -15394000 USD 2019-01-01 – 2019-12-31: -15394000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neurogene Inc. · 2019-12-31 Neurogene Inc. (edgar:1404644) Operating Cash Flow: -15394000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15394000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828021005630/nltx-20201231.htm#838971 Filing: 000162828021005630 The citation records this snapshot. The page link may show a newer release later.	USD 879,000 Exact value Exact value: 879000 USD 2019-01-01 – 2019-12-31: 879000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neurogene Inc. · 2019-12-31 Neurogene Inc. (edgar:1404644) Capital Expenditure: 879000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 879000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828021005630/nltx-20201231.htm#843857 Filing: 000162828021005630 The citation records this snapshot. The page link may show a newer release later.	−USD 16.27 million Calculation and evidence -15394000 − 879000 USD Exact free cash flow: -16273000 USD 2019-01-01 – 2019-12-31: -15394000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 879000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neurogene Inc. · 2019-12-31 Neurogene Inc. (edgar:1404644) Free cash flow: -16273000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15394000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828021005630/nltx-20201231.htm#838971 Filing: 000162828021005630 Input fundies:CapitalExpenditure: 879000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828021005630/nltx-20201231.htm#843857 Filing: 000162828021005630 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 33.28 million Exact value Exact value: -33277000 USD 2020-01-01 – 2020-12-31: -33277000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Neurogene Inc. · 2020-12-31 Neurogene Inc. (edgar:1404644) Net Income: -33277000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -33277000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828022004491/nltx-20211231.htm#947865 Filing: 000162828022004491 The citation records this snapshot. The page link may show a newer release later.	−USD 24.58 million Exact value Exact value: -24575000 USD 2020-01-01 – 2020-12-31: -24575000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neurogene Inc. · 2020-12-31 Neurogene Inc. (edgar:1404644) Operating Cash Flow: -24575000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24575000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828022004491/nltx-20211231.htm#875638 Filing: 000162828022004491 The citation records this snapshot. The page link may show a newer release later.	USD 2.22 million Exact value Exact value: 2219000 USD 2020-01-01 – 2020-12-31: 2219000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neurogene Inc. · 2020-12-31 Neurogene Inc. (edgar:1404644) Capital Expenditure: 2219000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2219000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828022004491/nltx-20211231.htm#878679 Filing: 000162828022004491 The citation records this snapshot. The page link may show a newer release later.	−USD 26.79 million Calculation and evidence -24575000 − 2219000 USD Exact free cash flow: -26794000 USD 2020-01-01 – 2020-12-31: -24575000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 2219000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neurogene Inc. · 2020-12-31 Neurogene Inc. (edgar:1404644) Free cash flow: -26794000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24575000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828022004491/nltx-20211231.htm#875638 Filing: 000162828022004491 Input fundies:CapitalExpenditure: 2219000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828022004491/nltx-20211231.htm#878679 Filing: 000162828022004491 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 60.69 million Exact value Exact value: -60692000 USD 2021-01-01 – 2021-12-31: -60692000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Neurogene Inc. · 2021-12-31 Neurogene Inc. (edgar:1404644) Net Income: -60692000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -60692000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312523216091/d522068ds4.htm#3739351 Filing: 000119312523216091 The citation records this snapshot. The page link may show a newer release later.	−USD 47.56 million Exact value Exact value: -47558000 USD 2021-01-01 – 2021-12-31: -47558000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neurogene Inc. · 2021-12-31 Neurogene Inc. (edgar:1404644) Operating Cash Flow: -47558000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -47558000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312523216091/d522068ds4.htm#3678326 Filing: 000119312523216091 The citation records this snapshot. The page link may show a newer release later.	USD 3.26 million Exact value Exact value: 3263000 USD 2021-01-01 – 2021-12-31: 3263000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neurogene Inc. · 2021-12-31 Neurogene Inc. (edgar:1404644) Capital Expenditure: 3263000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3263000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312523216091/d522068ds4.htm#3682226 Filing: 000119312523216091 The citation records this snapshot. The page link may show a newer release later.	−USD 50.82 million Calculation and evidence -47558000 − 3263000 USD Exact free cash flow: -50821000 USD 2021-01-01 – 2021-12-31: -47558000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 3263000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neurogene Inc. · 2021-12-31 Neurogene Inc. (edgar:1404644) Free cash flow: -50821000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -47558000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312523216091/d522068ds4.htm#3678326 Filing: 000119312523216091 Input fundies:CapitalExpenditure: 3263000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312523216091/d522068ds4.htm#3682226 Filing: 000119312523216091 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 55.2 million Exact value Exact value: -55200000 USD 2022-01-01 – 2022-12-31: -55200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Neurogene Inc. · 2022-12-31 Neurogene Inc. (edgar:1404644) Net Income: -55200000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -55200000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828024049615/ngne-20241202.htm#2222735 Filing: 000162828024049615 The citation records this snapshot. The page link may show a newer release later.	−USD 52.8 million Exact value Exact value: -52800000 USD 2022-01-01 – 2022-12-31: -52800000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neurogene Inc. · 2022-12-31 Neurogene Inc. (edgar:1404644) Operating Cash Flow: -52800000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -52800000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828024049615/ngne-20241202.htm#2223190 Filing: 000162828024049615 The citation records this snapshot. The page link may show a newer release later.	USD 2.23 million Exact value Exact value: 2230000 USD 2022-01-01 – 2022-12-31: 2230000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neurogene Inc. · 2022-12-31 Neurogene Inc. (edgar:1404644) Capital Expenditure: 2230000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2230000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828024049615/ngne-20241202.htm#2163080 Filing: 000162828024049615 The citation records this snapshot. The page link may show a newer release later.	−USD 55.03 million Calculation and evidence -52800000 − 2230000 USD Exact free cash flow: -55030000 USD 2022-01-01 – 2022-12-31: -52800000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 2230000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neurogene Inc. · 2022-12-31 Neurogene Inc. (edgar:1404644) Free cash flow: -55030000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -52800000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828024049615/ngne-20241202.htm#2223190 Filing: 000162828024049615 Input fundies:CapitalExpenditure: 2230000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000162828024049615/ngne-20241202.htm#2163080 Filing: 000162828024049615 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 36.3 million Exact value Exact value: -36300000 USD 2023-01-01 – 2023-12-31: -36300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Neurogene Inc. · 2023-12-31 Neurogene Inc. (edgar:1404644) Net Income: -36300000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -36300000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000012/ngne-20241231.htm#1636391 Filing: 000140464425000012 The citation records this snapshot. The page link may show a newer release later.	−USD 51.4 million Exact value Exact value: -51400000 USD 2023-01-01 – 2023-12-31: -51400000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neurogene Inc. · 2023-12-31 Neurogene Inc. (edgar:1404644) Operating Cash Flow: -51400000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -51400000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000012/ngne-20241231.htm#1636845 Filing: 000140464425000012 The citation records this snapshot. The page link may show a newer release later.	USD 321,000 Exact value Exact value: 321000 USD 2023-01-01 – 2023-12-31: 321000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neurogene Inc. · 2023-12-31 Neurogene Inc. (edgar:1404644) Capital Expenditure: 321000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 321000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000012/ngne-20241231.htm#1563895 Filing: 000140464425000012 The citation records this snapshot. The page link may show a newer release later.	−USD 51.72 million Calculation and evidence -51400000 − 321000 USD Exact free cash flow: -51721000 USD 2023-01-01 – 2023-12-31: -51400000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 321000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neurogene Inc. · 2023-12-31 Neurogene Inc. (edgar:1404644) Free cash flow: -51721000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -51400000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000012/ngne-20241231.htm#1636845 Filing: 000140464425000012 Input fundies:CapitalExpenditure: 321000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000012/ngne-20241231.htm#1563895 Filing: 000140464425000012 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 75.1 million Exact value Exact value: -75100000 USD 2024-01-01 – 2024-12-31: -75100000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Neurogene Inc. · 2024-12-31 Neurogene Inc. (edgar:1404644) Net Income: -75100000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -75100000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1374678 Filing: 000140464426000019 The citation records this snapshot. The page link may show a newer release later.	−USD 70.6 million Exact value Exact value: -70600000 USD 2024-01-01 – 2024-12-31: -70600000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neurogene Inc. · 2024-12-31 Neurogene Inc. (edgar:1404644) Operating Cash Flow: -70600000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70600000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1375132 Filing: 000140464426000019 The citation records this snapshot. The page link may show a newer release later.	USD 808,000 Exact value Exact value: 808000 USD 2024-01-01 – 2024-12-31: 808000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neurogene Inc. · 2024-12-31 Neurogene Inc. (edgar:1404644) Capital Expenditure: 808000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 808000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1332114 Filing: 000140464426000019 The citation records this snapshot. The page link may show a newer release later.	−USD 71.41 million Calculation and evidence -70600000 − 808000 USD Exact free cash flow: -71408000 USD 2024-01-01 – 2024-12-31: -70600000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 808000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neurogene Inc. · 2024-12-31 Neurogene Inc. (edgar:1404644) Free cash flow: -71408000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70600000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1375132 Filing: 000140464426000019 Input fundies:CapitalExpenditure: 808000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1332114 Filing: 000140464426000019 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 90.4 million Exact value Exact value: -90400000 USD 2025-01-01 – 2025-12-31: -90400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Neurogene Inc. · 2025-12-31 Neurogene Inc. (edgar:1404644) Net Income: -90400000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -90400000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1374523 Filing: 000140464426000019 The citation records this snapshot. The page link may show a newer release later.	−USD 77.2 million Exact value Exact value: -77200000 USD 2025-01-01 – 2025-12-31: -77200000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neurogene Inc. · 2025-12-31 Neurogene Inc. (edgar:1404644) Operating Cash Flow: -77200000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -77200000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1374948 Filing: 000140464426000019 The citation records this snapshot. The page link may show a newer release later.	USD 1.18 million Exact value Exact value: 1183000 USD 2025-01-01 – 2025-12-31: 1183000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neurogene Inc. · 2025-12-31 Neurogene Inc. (edgar:1404644) Capital Expenditure: 1183000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1183000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1331525 Filing: 000140464426000019 The citation records this snapshot. The page link may show a newer release later.	−USD 78.38 million Calculation and evidence -77200000 − 1183000 USD Exact free cash flow: -78383000 USD 2025-01-01 – 2025-12-31: -77200000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 1183000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neurogene Inc. · 2025-12-31 Neurogene Inc. (edgar:1404644) Free cash flow: -78383000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:47:29Z Snapshot: da2dbabee269956dea3c55b9376b247580a3dbaae605a56a2e67853ee4d7df5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1404644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -77200000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1374948 Filing: 000140464426000019 Input fundies:CapitalExpenditure: 1183000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm#1331525 Filing: 000140464426000019 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

98 filings · 2,777 latest values · 2,777 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001404644, 1404644, AQXP, NGNE, NLTX, edgar:1404644

Also known as AQUINOX PHARMACEUTICALS (USA) INC, AQUINOX PHARMACEUTICALS, INC, NEOLEUKIN THERAPEUTICS, INC., NEUROGENE INC., Neoleukin Therapeutics, Inc., Neurogene Inc.

Neurogene Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation